Search

Your search keyword '"Gallitano SM"' showing total 3 results
Start Over Author "Gallitano SM" Publisher mosby
3 results on '"Gallitano SM"'

1. Cutaneous findings in hospitalized and critically ill patients with COVID-19: A case series of 15 patients.

Author

Strom MA, Trager MH, Timerman D, Coromilas AJ, Burris K, Belsito DV, Eber A, Greenberg S, Husain S, Lewin JM, Naka F, Patrone CC, Coulon A, Cooper C, Bartholomew FB, Beck M, Dowd ML, Ensslin C, Gallitano SM, Loesch E, Malajian DM, Melnick L, Niedt GW, Uwakwe LN, Vu HL, Walther RR, Samie FH, and Geskin LJ

Subjects
Critical Illness, Hospitalization, Humans, COVID-19 complications, Skin Diseases etiology
Published
2021
Full Text
View/download PDF

3. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

Author

Gallitano SM, McDermott L, Brar K, and Lowenstein E

Subjects
Acquired Immunodeficiency Syndrome diagnosis, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome mortality, Adalimumab therapeutic use, Adult, Aged, Disease-Free Survival, Etanercept therapeutic use, Female, HIV Infections diagnosis, Humans, Infliximab therapeutic use, Male, Middle Aged, Monitoring, Physiologic methods, Prognosis, Quality Improvement, Randomized Controlled Trials as Topic, Severity of Illness Index, Survival Analysis, Treatment Outcome, Tumor Necrosis Factor-alpha administration & dosage, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, CD4-Positive T-Lymphocytes metabolism, HIV Infections drug therapy, HIV Infections mortality, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Patients with HIV and AIDS are living longer because of advancements in antiretroviral therapy. These patients are often susceptible to debilitating inflammatory disorders that are refractory to standard treatment. We discuss the relationship of tumor necrosis factor-alpha and HIV and then review 27 published cases of patients with HIV being treated with tumor necrosis factor-alpha inhibitors. This review is limited because no randomized controlled trials have been performed with this patient population. Regardless, we propose that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with tumor necrosis factor-alpha inhibitors., (Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results